
    
      Open Label, dose escalation in a 3+3 study design to establish the RP2D of the combination of
      ARQ761 and a PARP inhibitor, Olaparib. This is an exploratory Phase 1 trial evaluating the
      safety and tolerability of the combination of ARQ761 and Olaparib.
    
  